MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Models

iPSC-derived hepatocyte models replicating steatosis, insulin resistance, and inflammation.

Cryopreserved vials (1 × 10⁶ viable cells per vial) from defined donor backgrounds, PNPLA3, TM6SF2, and multiple wild-type backgrounds available
Inducible steatosis and lipid accumulation validated by BODIPY and cytokine readouts
Suitable for mechanistic and compound screening in metabolic disease pathways

Place your Order

Our MASLD pixHep™ model replicates the lipid accumulation, metabolic dysfunction, and inflammatory signalling of clinical steatosis.

Available in wild-type or genetic risk backgrounds, it provides a robust platform for screening metabolic modulators, anti-inflammatories, and disease progression blockers.

Lipid droplet accumulation confirmed by imaging.

Altered lipid metabolism and oxidative stress markers.

Compatible with CRISPR-driven genetic risk variants.

Co-culture ready for MASH progression modelling.

Technical Data & Functional Validation

Increased Lipid Accumulation

MASLD iPSC hepatocyte model showing lipid droplet accumulation

Insulin Resistance

pixHep MASLD hepatocytes showing reduced AKT phosphorylation following insulin stimulation 10-100nM indicating hepatic insulin resistance, normalized to total AKT and beta-actin — High-glucose-treated pixlbio pixHeps demonstrate reduced phosphorylation of AKT following stimulation with increasing concentrations of insulin (10-100nM) compared to vehicle-treated cells, indicative of hepatic insulin resistance. Protein data were normalized to total AKT and beta-actin and are presented as mean±SEM of n=3 independent experiments.

Lipotoxicity and Pro-Inflammation

pixHep MASLD hepatocytes showing reduced cell viability and increased pro-inflammatory cytokines IL-1β IL-6 IL-8 TNFα expression following high-fat treatment, mRNA normalized to 18S rRNA — **Left:** High-fat-treated pixlbio pixHeps demonstrate reduced cell viability compared to vehicle-treated cells, indicative of enhanced lipotoxicity. **Right:** High-fat-treated pixlbio pixHeps demonstrate increased expression of pro-inflammatory cytokine markers (IL-1β, IL-6, IL-8, TNFα) compared to vehicle-treated cells. mRNA data were normalized to 18S rRNA. All data are presented as mean±SEM of n=2-3 independent experiments.

Reduced Phase 1 Activity

pixHep CYP450 gene expression CYP3A4 CYP2B6 CYP2C9 CYP2A6 CYP2C19 CYP2J2 in vehicle high-glucose and high-fat treated hepatocytes, mRNA normalized to 18S rRNA — mRNA expression levels of the Phase 1 CYP450 genes CYP3A4, CYP2B6, CYP2C9, CYP2A6, CYP2C19, and CYP2J2 in vehicle-, high-glucose-, and high-fat treated pixHeps mRNA data were normalized to 18S rRNA and are presented as mean±SEM of n=2-3 independent experiments.

PNPLA3 Variant MASLD Phenotype

PNPLA3-mutant pixHep hepatocytes showing impaired AKT phosphorylation response to insulin 10-100nM compared to wild-type pixHep — AKT phosphorylation in PNPLA3-mutant pixHep following stimulation with increasing concentrations of insulin (10-100nM), revealing impaired response to insulin compared to wild-type pixHep.

MASH modeling through innovative co culture of iPSC-derived liver cell systems

Case Study

October 14, 2025

MASH modeling through innovative co culture of iPSC-derived liver cell systems

Streamline Your Research

Ready to Turn Your Cells Into Data?

Our pixCell portfolio seamlessly integrates into custom data generation projects—from functional assays (pixCellServices) to phenomic analysis (pixCellPaint)—delivering ready-to-use data at your fingertips.

pixCellPaint

pixCellServices